What Is Cagrilintide? Why Amylin May Be the Next Weight-Loss Hormone to Watch
For years, most of the medication conversation around weight management has centered on familiar pathways. A newer name is beginning to stand out for a different reason: cagrilintide.
What caught my attention is that cagrilintide is not simply another GLP-1 medication. It is a long-acting analogue of amylin, a hormone our bodies already use as part of the normal signaling around meals, fullness, and appetite.
What does amylin do?
Natural amylin is released from pancreatic beta cells along with insulin after we eat. One of its jobs is to help signal satiety. That makes the amylin pathway interesting for weight management because it approaches appetite from a different direction than the incretin medications many people are beginning to hear about.
Cagrilintide was designed to make that signal last longer, allowing once-weekly dosing in clinical research. In a Phase 2 dose-finding study involving adults with overweight or obesity without diabetes, researchers tested several weekly doses over 26 weeks.
The early weight-loss signal
The results were interesting. Across the cagrilintide doses studied, average weight reduction ranged from about 6.0% to 10.8% at 26 weeks, compared with about 3.0% with placebo. At the highest studied dose, average weight reduction was 10.8%, compared with 9.0% with daily liraglutide 3.0 mg.
The most common side effects were gastrointestinal, including nausea, constipation, and diarrhea. That part will sound familiar to anyone following modern weight-management medications, but the mechanism behind cagrilintide is different enough that I think the molecule deserves its own attention.
Where does the FDA fit into this?
At the Phase 2 stage, a medication is still well before an FDA decision. Phase 2 is where researchers learn much more about dose, efficacy, and tolerability. If that signal remains strong, the next major step is larger Phase 3 testing. Successful Phase 3 studies can eventually become part of the evidence submitted to the FDA for review.
So there is no approval decision to watch yet. What there is, however, is a new pathway worth following. We have spent a lot of time talking about GLP-1. Amylin may turn out to be another important part of the weight-management story.
What I am watching next
The big question is whether cagrilintide can build on these early results in larger trials—and whether combining an amylin analogue with another powerful appetite pathway could produce an even greater effect. That is where this story may get especially interesting.
Comments